The first three volumes of The Clinical Research Site Playbook were about establishing a stronger operating model: building your network, turning your CTMS into a recruitment engine, and standardizing eSource to create capacity. But building the infrastructure is only half the challenge. The other half is protecting it. Because the same sponsors who value your execution model can arrive with an ask that quietly undermines it: Use our system, not yours.
Every time that happens, the standardized workflows, trained coordinators, audit-ready processes, and technology infrastructure you’ve invested in get disrupted. One study at a time. That makes BYOT more than a technology preference. It’s an operating model strategy.
What Technology Coordination is Costing Clinical Research Sites
The clinical research site industry has gotten smarter about measuring operational costs.
Networks track coordinator hours, finance teams watch invoice aging, and start-up timelines get measured against benchmarks. But one cost category rarely appears on any dashboard: the ongoing burden of running systems you didn’t choose, didn’t train for, and don’t control. The scale of that burden is larger than most site leaders have priced out.
According to a 2025 survey conducted by the Tufts Center for the Study of Drug Development, 22% of investigative sites report financial losses directly tied to technology coordination burdens. Nearly one in four sites is losing money because of the friction between their own systems and the systems sponsors ask them to run.
For a single site, a sponsor-mandated system is a manageable cost. For a network, it is a structural liability; the same disruption, repeated across every site and every study.
Vol. 3 of this playbook series established the case for eSource standardization at the network level:
- Coordinators manage higher study volume because the protocol is embedded in the form
- Monitors resolve queries remotely because the data is digitally accessible
- Investigators produce audit-ready records on demand because nothing resides in a binder.
The model is built entirely on consistency — identical templates, identical compliance guardrails, identical workflows across every site. Each sponsor-mandated system introduced into that environment represents a direct breach of that standardization.
Once a subset of coordinators is operating on different data capture tools across different studies, the economics change.
- Training no longer scales because each new tool requires its own onboarding.
- Protocol enforcement becomes inconsistent across studies.
- And central oversight loses real-time visibility into execution, because the underlying data now resides in systems the network does not control.
The result is a network that built an integrated operating model, then allowed it to fragment, study by study, on terms set by sponsors rather than its own.
The sites that have invested most seriously in operational infrastructure, the ones with proven technology, trained staff, and consistent data quality, have the most to lose from continued system fragmentation. And they are also the ones with the most to gain from the model that is beginning to replace it.
What Is BYOT in Clinical Trials? A Guide for Site Networks
The sponsor needs your data. Not your system.
That distinction matters more than it sounds. When a sponsor requires a particular data capture platform, the stated reason is data quality, standardization, and oversight. Those are legitimate requirements. But a site running validated source data capture, with 21 CFR Part 11 compliance, documented change control, built-in audit trails, and a track record of clean monitoring outcomes, already meets them. The sponsor’s actual requirement is accurate, structured, timely, audit-trailed data. The system delivering it is not the specification. The data is.
BYOT makes that distinction practical. It creates a pathway for sites to demonstrate that their own validated systems meet or exceed what a sponsor would introduce, and to transfer data in a standardized format that sponsors can receive without requiring sites to run parallel workflows.
This framework was formalized in 2025 in the BYOT Playbook published by the Decentralized Trials & Research Alliance (DTRA). RealTime’s Founder and Chief Strategy Officer, Rick Greenfield, co-authored it alongside operations and technology leaders from GSK, Bristol Myers Squibb, Eli Lilly, Syneos Health, Medidata, Medable, and Mayo Clinic. It is not a vendor perspective. It is an industry consensus framework built by the people who run trials on all sides of the sponsor-site relationship.
The BYOT Playbook is worth reading in full. What this volume adds is the operational layer: what it actually takes to run BYOT, not just endorse it.
How BYOT Sites Demonstrate Technology Readiness
The BYOT framework introduces a concept called the Compliance Dossier, and this is where the philosophy becomes practice. A Compliance Dossier is a maintained, inspection-ready package that includes your system’s validation evidence, data security architecture, audit trail and eSignature documentation, change control records, and proof of adherence to FDA 21 CFR Part 11, ICH E6(R3), and applicable privacy regulations. Think of it as your site’s technology quality record, structured to share. A Compliance Dossier maintained at the network level tells a consistent story about your technology stack across every site and every study. That consistency is a signal that your organization knows what it is running, has validated it, and can demonstrate it on demand.
For sites running RealTime eSource, most of this documentation already exists. The platform’s 21 CFR Part 11 compliance architecture, automated audit trails, built-in change control records, and system validation documentation are maintained as part of how eSource operates.
How BYOT Changes the Sponsor Relationship for Clinical Research Site Networks
There are two versions of the technology conversation most site networks are having with sponsors right now.
The first: “We’d prefer to use our own system, but we understand if the protocol requires yours.”
The second: “Here’s our Compliance Dossier. Here’s our monitoring query rate from the last twelve months. Here’s how we’ve run this system across every site we operate. What do you need from us to move forward?”
The difference between those conversations is documentation, infrastructure, and demonstrated performance. It is also the difference between requesting an accommodation and negotiating as an equal partner.
Sites that can have the second conversation win more studies, start them faster, and run them with fewer friction points on both sides.
Sponsors who have seen what clean, structured, remotely accessible data looks like from a network with a mature, consistent eClinical stack increasingly prefer it to managing the execution variability that comes from provisioning every site with a system they’ve never used.
The University of the Sunshine Coast (UniSC) is one example of what the second conversation makes possible. Before implementing RealTime eSource, coordinators managed around 3 studies each. After standardizing on a site-controlled eSource platform, coordinators were handling 5 to 7 studies. Over five years, visit volume grew 2,850% without a proportional increase in headcount. That outcome is not possible on a technology stack that gets rebuilt with every new sponsor relationship.
The industry is moving toward a model where preferred network partners are defined not by site count but by execution consistency, data quality, and the ability to demonstrate both. BYOT, backed by a Compliance Dossier and a structured data transfer pathway, is how you build that case.
Key Takeaways
Technology fragmentation is a financial problem. Tufts CSDD data is direct: 22% of sites report financial losses tied to technology coordination burdens. Before the next sponsor-mandated system gets added to your stack, price out what running it actually costs in coordinator time, retraining, and parallel data entry.
BYOT is an operational posture, not a policy preference. A Compliance Dossier, validated systems, and a structured data transfer capability turn “we’d prefer to use ours” into a documented, defensible sponsor conversation. The framework exists. The regulatory backing exists. The missing piece is usually the documentation.
The network that controls its technology stack controls its margins. Every study running on your own validated platform, is a study where your coordinators aren’t retraining, your templates aren’t being rebuilt, and your operating model isn’t being fragmented. Ultimately, this becomes a competitive advantage.
Connect with an expert to see RealTime eSource in action.
Download the BYOT Playbook from DTRA.
Read the full playbook series:
Vol. 1: The State of Site Networks 2026
Vol. 2: Your CTMS is a Recruitment Engine — Are You Using it That Way?